TY - JOUR
T1 - Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020
AU - Members of the Research Committee for IgG4-related Disease supported by the Ministry of Health, Labour, Welfare of Japan, Japan Pancreas Society
AU - Okazaki, Kazuichi
AU - Kawa, Shigeyuki
AU - Kamisawa, Terumi
AU - Ikeura, Tsukasa
AU - Itoi, Takao
AU - Ito, Tetsuhide
AU - Inui, Kazuo
AU - Irisawa, Atsushi
AU - Uchida, Kazushige
AU - Ohara, Hirotaka
AU - Kubota, Kensuke
AU - Kodama, Yuzo
AU - Shimizu, Kyoko
AU - Tonozuka, Ryosuke
AU - Nakazawa, Takahiro
AU - Nishino, Takayoshi
AU - Notohara, Kenji
AU - Fujinaga, Yasunari
AU - Masamune, Atsushi
AU - Yamamoto, Hiroshi
AU - Watanabe, Takayuki
AU - Nishiyama, Toshimasa
AU - Kawano, Mitsuhiro
AU - Shiratori, Keiko
AU - Shimosegawa, Tooru
AU - Takeyama, Yoshifumi
N1 - Funding Information:
This work was supported by MHLW Research Program on Rare and Intractable Diseases Grant Number JPMH20FC1040. The evaluation committee members selected from the AIP committee of the Japan Pancreas Society are as follows: Yoshifumi Takeyama M.D. (Kindai University), Dai Inoue M.D. (Kanazawa University), Hiroyuki Irie M.D. (Saga University), Eisuke Iwasaki M.D. (Keio University), Toshiharu Ueki M.D. (Fukuoka University), Takeshi Uehara M.D. (Shinshu University), Atsushi Kanno M.D. (Jichi Medical University), Shigeru Ko M.D. (Keio University), Junichi Sakagami M.D. (Fukuchiyama Municipal Hospital), Norikazu Shinkura M.D. (Aizawa Hospital), Minoru Tada M.D.(Chiba National Medical Center), Hideaki Hamano M.D. (Shinshu University), Kenji Hirano M.D. (Tokyo Takanawa Hospital), Yoshiki Hirooka M.D. (Fujita Medical University), Mitsuhiro Masuda M.D. (Kobe University), and Nobumasa Mizuno M.D. (Aichi Cancer Center Hospital), Hitoshi Yoshida M.D.(Showa University)
Funding Information:
This work was supported by MHLW Research Program on Rare and Intractable Diseases Grant Number JPMH20FC1040. The evaluation committee members selected from the AIP committee of the Japan Pancreas Society are as follows: Yoshifumi Takeyama M.D. (Kindai University), Dai Inoue M.D. (Kanazawa University), Hiroyuki Irie M.D. (Saga University), Eisuke Iwasaki M.D. (Keio University), Toshiharu Ueki M.D. (Fukuoka University), Takeshi Uehara M.D. (Shinshu University), Atsushi Kanno M.D. (Jichi Medical University), Shigeru Ko M.D. (Keio University), Junichi Sakagami M.D. (Fukuchiyama Municipal Hospital), Norikazu Shinkura M.D. (Aizawa Hospital), Minoru Tada M.D.(Chiba National Medical Center), Hideaki Hamano M.D. (Shinshu University), Kenji Hirano M.D. (Tokyo Takanawa Hospital), Yoshiki Hirooka M.D. (Fujita Medical University), Mitsuhiro Masuda M.D. (Kobe University), and Nobumasa Mizuno M.D. (Aichi Cancer Center Hospital), Hitoshi Yoshida M.D.(Showa University)
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - In response to the latest knowledge and the amendment of the Japanese diagnostic criteria for autoimmune pancreatitis (AIP) in 2018, the Japanese consensus guidelines for managing AIP in 2013 were required to be revised. Three committees [the professional committee for developing clinical questions (CQs) and statements by Japanese specialists; the expert panelist committee for rating statements by the modified Delphi method; and the evaluating committee of moderators] were organized. Twenty specialists in AIP extracted the specific clinical statements from a total of 5218 articles (1963–2019) from a search in PubMed and the Cochrane Library. The professional committee made 14, 9, 5, and 11 CQs and statements for the current concept and diagnosis, extra-pancreatic lesions, differential diagnosis, and treatment, respectively. The expert panelists regarded the statements as valid after a two-round modified Delphi approach with individually rating these clinical statements, in which a clinical statement receiving a median score greater than 7 on a 9-point scale from the panel was regarded as valid. After evaluation by the moderators, the amendment of the Japanese consensus guidelines for AIP has been proposed in 2020.
AB - In response to the latest knowledge and the amendment of the Japanese diagnostic criteria for autoimmune pancreatitis (AIP) in 2018, the Japanese consensus guidelines for managing AIP in 2013 were required to be revised. Three committees [the professional committee for developing clinical questions (CQs) and statements by Japanese specialists; the expert panelist committee for rating statements by the modified Delphi method; and the evaluating committee of moderators] were organized. Twenty specialists in AIP extracted the specific clinical statements from a total of 5218 articles (1963–2019) from a search in PubMed and the Cochrane Library. The professional committee made 14, 9, 5, and 11 CQs and statements for the current concept and diagnosis, extra-pancreatic lesions, differential diagnosis, and treatment, respectively. The expert panelists regarded the statements as valid after a two-round modified Delphi approach with individually rating these clinical statements, in which a clinical statement receiving a median score greater than 7 on a 9-point scale from the panel was regarded as valid. After evaluation by the moderators, the amendment of the Japanese consensus guidelines for AIP has been proposed in 2020.
KW - Autoimmune pancreatitis
KW - Delphi method
KW - Diagnosis
KW - Guidelines
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85127729768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127729768&partnerID=8YFLogxK
U2 - 10.1007/s00535-022-01857-9
DO - 10.1007/s00535-022-01857-9
M3 - Review article
C2 - 35192048
AN - SCOPUS:85127729768
SN - 0944-1174
VL - 57
SP - 225
EP - 245
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 4
ER -